Study Shows CGMs Help Type 1s Achieve Better Blood Sugar Control-Especially Those Over 25

The study shows that the success of a CGM may depend on the age of the user.

Sep 11, 2008

A study sponsored by the Juvenile Diabetes Research Foundation confirms that many older type 1 patients achieve better control of their blood sugar levels by using a continuous glucose monitor (CGM) than by conventional monitoring with a meter and finger pricks. 

The study also shows that the success of a CGM may depend on the age of the user.

CGMs use tiny sensors embedded under the skin to report blood glucose levels up to several hundred times a day. The data allow users to track upward and downward blood sugar trends, to which they can respond with exercise, insulin doses, or changes in food intake.

The study, published on September 8, 2008, in the New England Journal of Medicine, used CGMs from three manufacturers: Abbott Laboratories (Free Style Navigator), DexCom, Inc. (DexCom Seven), and Medtronic, Inc. (MiniMed insulin pump and CGM). Abbott and Johnson & Johnson supplied the home glucose meters

Over six months, the study tracked 322 type 1s who were receiving intensive therapy in the form of either insulin pump use or more than three daily injections of insulin. The patients were divided into two groups: the first group, with 165 patients, used CGMs exclusively, while the second group of 157 patients used traditional home glucose meters and test strips.

The patients were further divided into three age groups: eight- to 14-year-olds (114 patients); 15- to 24-year-olds (110 patients); and those 25 years and older (98 patients).

By the end of the study, the 25 and older group saw a 0.53% reduction in average A1c. (The mean baseline A1c level for all study patients was 8%.) 

The study reported no statistically significant reductions in A1c levels for the two younger patient groups. The researchers attributed these results to each group's rate of use. In the 25 and older group, 83 percent of the patients used the CGM at least six days a week, compared to only 30 percent of the 15- to 24-year-old group.

Among the eight- to 14-year-old group, who might have been expected to record an even lower rate of use, 50 percent used the CGM six days or more per week. That figure may have resulted from greater parental involvement with younger patients.

The study's results add more weight to the case for CGM reimbursement by insurance companies, an argument that manufacturers, physicians, and patients have been making for some time. By giving people with diabetes the tools to control their blood sugar levels, the insurance companies will pay less down the line to treat the retinopathy, vascular disease, and kidney problems that often result from uncontrolled blood sugar. In the long run, paying for CGMs will have a beneficial effect on insurance company profit margins.

Click Here To View Or Post Comments

Categories: A1c Test, Blood Glucose, Blood Sugar, CGMs, Diabetes, Diabetes, Food, Insulin, Insulin Pumps, Research, Type 1 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (1)

You May Also Be Interested In...


Comments

Posted by Anonymous on 28 May 2009

I have been denied no matter what my Dr. writes to BCBS of Michigan, no matter how I appeal the denial, and no matter what reports like this one comes out. I truly believe in the last statement; “By giving people with diabetes the tools to control their blood sugar levels, the insurance companies will pay less down the line to treat the retinopathy, vascular disease, and kidney problems that often result from uncontrolled blood sugar. In the long run, paying for CGMs will have a beneficial effect on insurance company profit margins."
I am just at a loss as to the intelligence level of the people making the decisions at these ins. companies. Do they ever think these types of decisions through or do they just base it on the bottom line, no matter the impact to the end user.


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.